Phase I Trial of Abexinostat Combined With Palbociclib and Fulvestrant in Patients With Antiestrogen Refractory ER+, HER2- Breast Cancer and Gynecological Metastatic Tumors
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Abexinostat (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 14 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Feb 2021 Planned initiation date changed from 1 Jan 2021 to 31 Mar 2021.
- 30 Nov 2020 Planned End Date changed from 31 Jan 2022 to 30 Jun 2025.